What is the YK-11 dosage?

What the sources give for a YK-11 dose and schedule
StudyDose and scheduleAnimals
Horse study of metabolites in urine and plasma (Harding, 2023)1Three daily doses of 50 mg, oralTwo Thoroughbred horses
Rat study (Dahleh, 2023)20.35 g/kg in a five-week protocol beside control, swimming-exercise and exercise plus YK11 groups; route, frequency and number of rats not given in the study summaryMale Wistar rats
Rat study (Dahleh, 2024)30.35 g/kg in a 5-week experiment beside control, swimming-exercise and exercise plus YK11 groups; route, frequency and number of rats not given in the study summaryRats

No label, registry entry or human trial found states a YK-11 dose; the animal studies found gave 50 mg orally as three daily doses to two Thoroughbred horses (Harding, 2023)1 and 0.35 g/kg to male Wistar rats over five weeks (Dahleh, 2023).2

What the sources give for a YK-11 dose and schedule

The table is set at the top of the page

These are doses from horse and rat studies, not human ones.123

For cycle length, a 2025 systematic review of 72 articles (Vasireddi) reports that thirteen case reports described 15 cases of SARM abuse; all patients were men, with a median age of 32 years, and all ingested SARMs orally for a mean course of 8 weeks; its summary covers SARMs in general and does not name YK-11.4 The same review says athletes reported consuming SARMs, as a class, at much higher doses than clinically studied, which it says may increase the risk of the reported side effects, such as liver injury, impaired insulin sensitivity, cardiovascular events, and tendon damage.4 How cycles are usually described is in the cycles guide, and two other SARMs are covered in the ostarine and ligandrol guides.

How YK-11 is supplied and why there is no volume to convert

No label or maker leaflet found gives a YK-11 strength, a mixing instruction or a concentration, so there is no figure to convert to a volume. The horse study says YK-11 is easily accessible via internet-based supplement vendors.1 The FDA says SARM products are often sold with no warnings on the labels, are sometimes "for research purposes" or "not for human consumption", and have been sold directly to consumers for human use with dosing instructions.5 A screening of 60 dietary supplements bought online and directly from international vendors in 2020 (Lee, 2021) detected YK-11, not disclosed on the label, in some products.6

Regulatory and sport status

The FDA describes bodybuilding products that often contain SARMs as unapproved drugs it has not reviewed for safety and effectiveness.5 A DailyMed search for yk-11 and ykarine returned no label, so no approved label or official dose for YK-11 turned up. Its laboratory tested GE Labs Ykarine after an adverse event report of a consumer who used the product and subsequently suffered a stroke; it found undeclared trendione, an anabolic steroid, and confirmed the product contains YK-11, a listed ingredient on the label.5 The WADA 2026 Prohibited List names YK-11 among the SARMs and prohibits anabolic agents at all times, in and out of competition.7 More on the class is on the SARMs page and the YK-11 page, and Cardarine is covered in how to take Cardarine.

How YK-11 is stored

No label or maker storage conditions for YK-11 were found, before or after dissolving. The supplement-screening study (Lee, 2021) says YK-11 is easily hydrolysed in just a few hours, without giving storage conditions in its summary, and it confirmed hydrolysed YK-11 under acidic conditions by NMR spectral data; this is a laboratory finding, not a storage instruction.6 It also calls YK-11 particularly unstable in its mass-spectrometry analysis.6

Frequently asked questions

Has YK-11 been tested in a human clinical trial?

ClinicalTrials.gov searches for yk-11 and YK11 returned no studies, and PubMed searches for YK-11 human dose and YK-11 clinical trial found only cell, animal and analytical studies and one doping-control letter.

What do cell studies of YK-11 show?

A cell study (Kanno, 2011) found YK11 to be a partial agonist of the androgen receptor in an androgen responsive element (ARE)-luciferase reporter assay.8 A study in C2C12 mouse myoblast cells (Kanno, 2013) reports that YK11 treatment, but not DHT, induced the expression of follistatin in the cells.9

References

  1. PubMed. Equine metabolism of the selective androgen receptor modulator YK-11 in urine and plasma following oral administration. 2023. pubmed.ncbi.nlm.nih.gov
  2. PubMed. YK11 induces oxidative stress and mitochondrial dysfunction in hippocampus: The interplay between a selective androgen receptor modulator (SARM) and exercise. 2023. pubmed.ncbi.nlm.nih.gov
  3. PubMed. From gains to gaps? How Selective Androgen Receptor Modulator (SARM) YK11 impact hippocampal function: In silico, in vivo, and ex vivo perspectives. 2024. pubmed.ncbi.nlm.nih.gov
  4. PubMed. Athlete Selective Androgen Receptor Modulators Abuse: A Systematic Review. 2025. pubmed.ncbi.nlm.nih.gov
  5. US FDA. Bodybuilding Products: SARMs Cause Harm. fda.gov
  6. PubMed. Development and validation of liquid chromatography-tandem mass spectrometry method for screening six selective androgen receptor modulators in dietary supplements. 2021. pubmed.ncbi.nlm.nih.gov
  7. WADA. WORLD ANTI-DOPING CODE. wada-ama.org
  8. PubMed. (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor. 2011. pubmed.ncbi.nlm.nih.gov
  9. PubMed. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. 2013. pubmed.ncbi.nlm.nih.gov